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The 2005 American Society of Transplant Surgeons
(ASTS) Winter Symposium entitled ‘The Art and Sci-
ence of Immunosuppression’ explored ways to max-
imize existing immunosuppressive protocols and to
develop new strategies incorporating novel agents
and emerging diagnostic technologies to customize
immunosuppression and reduce side effects. Several
presentations evaluated steroid withdrawal or avoid-
ance protocols reflecting the significant difficulties
of bone loss, glucose control and growth retarda-
tion in children associated with long-term steroid use.
Calcineurin-inhibitor related renal dysfunction of both
native and transplanted kidneys was identified as sig-
nificant, but no consensus was reached concerning
effective prevention. Similarly, recurrence of Hepati-
tis C following liver transplantation was identified as
problematic without identifying a preferred immuno-
suppressive regimen in this setting. Control of T-cell
mediated rejection was found to be excellent, but
recognition and treatment of non-T cell causes of allo-
graft damage (i.e. B- or NK-cell mediated) was identi-
fied as an area of current interest. Immunosuppressive
agents under development, such as those blocking co-
stimulation or cytokine signals, and JAK-3 inhibitors
were discussed. Finally, the available technologies for
molecular and genetic diagnostics and the clinical cor-
relation in the post-transplant setting were discussed.
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Introduction
During the last 50 years, solid organ transplantation has
changed from a modestly successful therapy offered only
to patients with renal failure to a highly successful ther-
apy offered to patients with end-stage failure of the kid-
ney, liver, pancreas, intestine, lung or heart. Much of this
change can be attributed to improvements in immunosup-
pression that have dramatically lowered acute cellular re-
jection rates, thereby facilitating extrarenal organ transplan-
tation with acceptable patient and graft survival. In the last
10 years, new classes of immunosuppressive drugs with
varying potency and side effect profiles have reached
the clinic. Moreover, molecular diagnostics have emerged
as practical strategies to monitor individual immune re-
sponses in real time. Armed with these new tools, the
transplantation community can now envision designing
and manipulating immunosuppression to fit individual re-
cipients, maximizing outcomes and minimizing morbidity.
The Fifth Annual American Society of Transplant Surgeons’
State-of-the-Art Winter Symposium aimed to explore the
current art and science of immunosuppression.
Overview
As the keynote speaker, Halloran (University of Alberta)
highlighted broad opportunities for the science of immuno-
suppression to improve patient outcomes. He suggested
that improved immunosuppression in contrast to tolerance
induction, was the more realistic means of achieving what
he identified as the Holy Grail of transplantation: ‘healthy
patients with healthy grafts’. Halloran proposed that the
best immunosuppression stabilizes a patient’s adaptive re-
sponse to their graft and suggested that better immuno-
suppression is predicated on a sophisticated and complete
understanding of rejection processes. He also questioned
the adequacy of traditional notions of acute rejection as




Recent reports show various cell types present during
acute rejection in allograft biopsies indicating heteroge-
neous mechanisms despite homogeneous histopathology
(1). He presented his own work in a murine renal model
showing that reproducible patterns of gene expression
characteristic of rejection appear well before histological
changes or renal dysfunction. Defining the molecular sig-
nature(s) of rejection-associated events may afford oppor-
tunities to assess the presence and strength of effector
mechanisms that may cause damage rather than the actual
damage itself (2). Moreover, it may be possible to establish
molecular profiles associated with stable graft function or
toxicities, and to use these profiles to guide therapeutic
interventions and clinical management (1–3). Finally, Hal-
loran suggested that these techniques be applied to the
investigation of both humoral and chronic rejection, both
of which must be controlled if transplantation outcomes
are to be further improved.
The Art Of Immunosuppression
Minimization strategies
The extended survival of transplant patients has resulted
in an increased cumulative burden of side effects from
immunosuppression including renal dysfunction, viral in-
fections, metabolic abnormalities and malignancies (4–
6). Magee (University of Michigan) highlighted the inci-
dence of chronic renal insufficiency among transplant re-
cipients. Among non-renal transplant recipients, 16.5% de-
veloped chronic renal insufficiency and 4.8% progressed
to end-stage renal disease, which is associated with a
substantial risk of death (hazard ratio 4.55; 95% confi-
dence interval 4.38–4.74) (6). Unfortunately, there is lim-
ited information as to optimal strategies to minimize renal
compromise as reports of delayed initiation, withdrawal
or minimization of calcineurin inhibitors to improve renal
function are frequently from small, retrospective, single-
center studies with limited follow-up. Currently, the most
prudent approach appears to be heightened awareness
to identify those at risk, targeting them for early and
aggressive medical interventions such as those gener-
ally recommended for other etiologies of chronic renal
insufficiency.
The serious morbidity associated with immunosuppres-
sion has motivated efforts to develop minimization strate-
gies. A major emphasis has been to reduce or eliminate cor-
ticosteroids. In renal transplantation where such strategies
have been extensively studied, a common theme has been
the use of either polyclonal or monoclonal anti-lymphocyte
antibody induction therapy to compensate for the lack of,
or rapid withdrawal of steroids in the early post-transplant
period. Complete steroid avoidance has even been applied
to pediatric transplantation. Sarwal reported the Stanford
experience with 57 pediatric kidney recipients treated with
extended (pre-operative – 6 months postoperatively) da-
clizumab induction followed by tacrolimus and mycophe-
nolate mofetil (MMF) maintenance immunosuppression
(7). At three years, the 6% incidence of acute rejection
in the steroid-free group compared favorably to the 30%
incidence observed for historical controls. Steroid-free im-
munosuppression was also associated with a significant
growth advantage.
The deleterious impact of corticosteroids on glucose con-
trol has logically suggested that minimizing steroid expo-
sure may be particularly desirable for pancreas or islet
transplantation. Kaufmann (Northwestern University Medi-
cal School) summarized multiple single-center experiences
including that of the group in Nantes, France who found
no clinically significant differences between steroid avoid-
ance versus steroid withdrawal in pancreas transplant re-
cipients induced with RATG induction and maintained on
cyclosporine and MMF (8). Similarly, the University of Min-
nesota has used RATG and basiliximab induction, followed
by tacrolimus and sirolimus maintenance with similar out-
comes. Northwestern has reported excellent 3-year graft
survival, low acute rejection rates (<15%), and a signif-
icant decrease in the incidence of CMV disease in high
risk patients compared to those receiving steroids in 200
pancreas recipients who received either RATG or alem-
tuzumab induction followed by steroid free maintenance
immunosuppression (tacrolimus + sirolimus). Kaufmann
concluded that the use of a T-cell depleting agent enabled
steroid avoidance with excellent patient and graft survival,
low acute rejection rates, and decreased steroid-related
side effects.
Successful steroid sparing regimens have also been re-
ported in liver transplantation. Eason (The Ochsner Clinic)
spoke of testing polyclonal rabbit anti-thymocyte globulin
(RATG) induction followed by tacrolimus monotherapy in
a prospective, randomized trial. Compared to the group
receiving tacrolimus and steroids, the RATG-tacrolimus
monotherapy group had less post-transplant diabetes, cy-
tomegalovirus (CMV) infection, and steroid-requiring re-
jection (9). Investigators in Germany and Italy have also
demonstrated encouraging results with steroid-free pro-
tocols using basiliximab induction (10,11). To date, none
of these protocols appear to adversely affect patients in-
fected with hepatitis C.
In addition to corticosteroid minimization, several centers
have eliminated anti-metabolites, using a regimen of induc-
tion followed by tacrolimus monotherapy. Shapiro (Pitts-
burgh) reported that kidney transplant patients induced
with antibody and maintained on tacrolimus monotherapy
could be weaned over the first year to once or twice weekly
dosing with superior patient and graft survival compared to
patients receiving standard immunosuppression. Groups
from Miami (12), New Orleans (9) and Pittsburgh (13) report
being able to successfully maintain liver transplant patients
at very low or undetectable levels of tacrolimus following
induction, but were less successful at weaning these pa-
tients to spaced monotherapy.
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Perhaps the ultimate in minimization strategies is to induce
tolerance. Cosimi (Massachusetts General Hospital) pre-
sented an overview of his trial for one-haplotype matched
kidney transplant recipients using the tolerance induction
protocol, which had previously been used in the setting of
two-haplotype matched kidney transplant recipients (14).
Patients underwent a rigorous conditioning regimen of
thymic irradiation, cyclophosphamide and treatment with
MEDI-507, a monoclonal antibody directed against CD2
in preparation for simultaneous donor bone marrow infu-
sion and kidney transplantation. Cyclosporine monother-
apy was used for maintenance immunosuppression. Three
patients were treated; one was weaned off cyclosporine
without incident, the second was eventually weaned but
experienced a humoral rejection, and the third lost the
graft to aggressive humoral rejection. The rejections were
thought to be related to MEDI-507’s inability to deplete B
cells; the protocol will resume with the addition of ritux-
imab (anti-CD20).
Non-T-cell mediated immune processes
The traditional focus of immunosuppression has been to
control activation and proliferation of T cells. Ever since
crossmatching protocols eliminated hyperacute rejection,
antibody-mediated processes driven by B cells were con-
sidered to be infrequent and unimportant. Recently, how-
ever, it has become known that antibody-mediated rejec-
tion (AMR) is a frequent component of acute cellular rejec-
tion and, less frequently, can occur independently.
The target of AMR for all transplanted organs is thought
to be endothelial cells, but the histopathological picture
varies with the transplanted organ (15). Recipients of kid-
ney and heart allografts have the highest incidence of docu-
mented AMR. The most reliable histological finding of AMR
is demonstration of C4d deposition in capillary endothelium
(16). Currently, C4d immunofluorescence or immunohisto-
chemistry may not be routinely performed and may need
to be specifically requested if AMR is suspected.
Concomitant with the ability to diagnose antibody-
mediated processes has been the emergence of treat-
ment strategies for AMR or pre-transplant sensitization
(17). Typically regimens neutralize and/or deplete circulat-
ing donor-specific anti-HLA antibodies. Collaborative trials
are now underway to optimize patient evaluation and se-
lection, as well as protocol specifics. Most trials combine
plasmapheresis to deplete pre-existing antibody, IVIg to in-
activate any remaining antibody, anti-B-cell agents such as
rituximab or, occasionally splenectomy, to prevent future
antibody production.
While the strategies discussed above address pre- and
peri-transplant antibody-mediated processes, there is now
increasing concern that antibody-mediated processes may
also be operative long after transplantation. HLA antibod-
ies produced following transplantation cause a cycle of
endothelial damage and repair leading to vessel constric-
tion and subsequent ischemic parenchymal injury. Terasaki
(UCLA) presented data regarding the clear association of
high levels of anti-donor antibodies and the development of
chronic rejection resulting in inferior patient and graft sur-
vival after kidney transplantation (18). Since antibody depo-
sition in vessels appear to precede constrictive arteriopathy
by several years, periodic screening of transplant recipients
for HLA antibodies and consideration of immunosuppres-
sion manipulation for those patients in whom antibodies
are found may be warranted, particularly if efficacious treat-
ment strategies are developed.
Madsen (Massachusetts General Hospital) discussed an-
other type of non-T-cell mediated allograft damage involv-
ing natural killer (NK) cells and the various cytokines they
produce. NK cells are a primary component of the innate
immune response and, therefore, do not require prior anti-
gen exposure or sensitization to antigen in order to acti-
vate. It is thought that self-MHC antigens prevent NK-cell
activation, while the absence of ‘self’ MHC promotes ac-
tivation. Teleologically, this mechanism was intended to
protect against infectious agents. Consequently, the trans-
plant setting might represent a constant and powerful stim-
ulus for NK-cell activation. NK-cell activation and elabora-
tion of cytokines have been implicated in the pathogenesis
of chronic allograft damage in the form of chronic rejection
in kidney and liver allografts, vasculopathy in cardiac allo-
grafts and bronchiolitis obliterans in lung allografts (19). In-
hibition of the mammalian target of rapamycin (mTOR) may
mitigate the development of these conditions (20,21).
When art (and science) fails
In spite of the remarkable success of immunosuppression,
clinical scenarios arise daily which question our immuno-
suppression practices. Matas (University of Minnesota)
discussed clinical management strategies to be employed
when immunosuppression fails, as connoted by the oc-
currence of acute rejection. Determining why rejection oc-
curred in the first place is critical to decision making. If there
was failure to achieve the intended regimen, efforts should
optimize dosing and/or compliance. If the regimen itself
failed, then immunosuppression should be intensified. For
example, conversion from cyclosporine to tacrolimus at the
time of acute rejection facilitated resolution of the index
episode for kidney and lung recipients and reduced the risk
of recurrent rejection for kidney recipients (22,23). Unfortu-
nately, the literature remains fairly silent with regard to the
appropriate maintenance immunosuppression in the set-
tings of acute humoral rejection, subclinical rejection, late
acute rejection and chronic rejection.
In the arena of liver transplantation, Feng (University of Cal-
ifornia, San Francisco) presented evidence that immuno-
suppression practices may impact the tempo and severity
of recurrent hepatitis C (HCV). The natural history of re-
current HCV is clearly accelerated compared to primary
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infection (24). While multiple studies have shown that bo-
lus corticosteroids or OKT3 to treat rejection enhanced
HCV progression and worsened outcomes (25–29), two
more recent reports claim that rapid corticosteroid taper
accelerated fibrosis (30,31). Uncertainty regarding the spe-
cific effects of various immunosuppressants on recurrent
disease is further exacerbated by the diagnostic ambigu-
ity between acute rejection and recurrent HCV (32). There-
fore, there is substantial need to clarify the impact of induc-
tion, maintenance, and anti-rejection immunosuppression
strategies on recurrent HCV.
The Science of Immunosuppression
There is increasing awareness that immunosuppressants
may have biologic and/or immunologic effects well beyond
their recognized anti-rejection mechanisms.
Homeostatic proliferation
The depletional strategies increasingly used for induction
immunosuppression are known to dramatically alter the
circulating lymphocyte population for prolonged periods of
time. There is evidence that, upon reconstitution of the
lymphocyte compartment, an inverse CD4:CD8 ratio de-
velops and persists for many years (33). The phenotype of
these cells appears to be that of memory rather than naı̈ve
cells. Since memory cells have a lower threshold for acti-
vation compared to naı̈ve cells, these agents may have sig-
nificant implications for the long-term control of anti-donor
immune responses.
Regulatory T cells
Normally, regulatory T cells respond to antigenic stimula-
tion by inhibiting the proliferation of naı̈ve antigen-specific
cells by direct cell-to-cell contact or the elaboration of solu-
ble factors. Generation of donor-specific regulatory cells re-
quires that lymphocyte activation occurs in an appropriate,
conducive milieu. Most immunosuppressive agents inhibit
T-cell activation and therefore may simultaneously inhibit
the generation of regulatory T cells. Experimental work
from Emory (34) and Oxford (35) show that calcineurin in-
hibitors diminish or abrogate regulatory activity, whereas
mTOR inhibitors do not.
Immunosuppressants in the pipeline
Bromberg (Mount Sinai School of Medicine) reviewed the
immunobiology of mammalian responses to alloantigen,
pointing out that its very complexity offers multiple targets
for directed or engineered immunosuppressive agents
(36). While T cells and the receptors involved in actual anti-
gen recognition (Signal 1) have historically been the prime
targets, the various components of the co-stimulatory path-
way (Signal 2) and the inflammatory cytokines that pro-
vide Signal 3, as well as antigen presenting cells have
become the new targets of immunosuppressant drug
development.
Co-stimulatory blockade agents
Rodent models of transplantation and, to a lesser extent,
non-human primate models, have shown that interruption
of co-stimulatory pathways can produce remarkable pro-
longation of allograft survival (37). Initial clinical trials con-
ducted in patients with idiopathic thrombocytopenia pur-
pura (ITP) using a monoclonal antibody directed against
CD40 (5C8) suggested the product was safe and effica-
cious. However, when trials in renal transplant patients be-
gan, significant complications of serious thromboembolic
events occurred. This, coupled with the lack of efficacy, led
to the termination of the study. A second monoclonal an-
tibody (IDEC-131) directed against a different component
of the co-stimulatory pathway (CD154) has been tested
clinically. There were no safety issues demonstrated; how-
ever, there was also no efficacy. A third monoclonal, Chi20,
is a chimeric anti-human CD40 antibody that has shown
promise by itself and in combination with LEA29Y (high
affinity CTLA4Ig) in primate models, but has yet to be
tested clinically.
Beyond T cells and co-stimulatory blockade
Vincenti (University of California, San Francisco) outlined
a highly novel immunosuppression strategy proposed
by Strom combining both established and novel agents
selected for their complementary and tolerance-friendly
mechanisms (38). The triple regimen uses IL2Fc to en-
hance apoptosis-induced cell death, mIL15Fc to blocks pro-
liferative and anti-apoptotic activity, and mTOR inhibition
(sirolimus) to block the expansion of alloreactive cells while
and spare regulatory T cells.
Bromberg discussed FTY720, a unique drug cur-
rently in clinical trials that protects transplanted or-
gans by preventing the egress of lymphocytes after
chemokine-driven migration into lymph nodes (39,40). First
(Astellas, Inc.) described experimental and early clinical
trial results for FK778, a malononitrilamide with both
anti-T- and B-cell activity, which reduces production of
cytokines (including TGF-b) are implicated in the develop-
ment of allograft fibrosis. Perhaps the most exciting as-
pect of FK778 is its apparent activity against BK polyoma
virus.
Finally, Chan (Pfizer Global Research & Development) de-
scribed an inhibitor of JAK3, a tyrosine kinase of the
Janus family, present primarily in lymphocytes and in-
volved in signal transduction initiated by the c -chain
shared by the receptors for IL-2, 4, 7, 9, 15, and 21.
The inhibitor (CP-690,550), by specifically targeting the
common c -chain, may be able to overcome the widely
acknowledged redundancy of the immune system. JAK-
3 inhibition has been shown to prolong allograft survival
with minimal toxicity in a non-human primate kidney trans-
plant model with minimal toxicity (41). Clinical trials of
all of these agents are either underway or are being
planned.
278 American Journal of Transplantation 2006; 6: 275–280
The Art and Science of Immunosuppression
Immunologic profiling
Recent advances in molecular and genetic diagnostics
have suggested that various post-transplant disease states
such as rejection and infection are associated with specific
gene expression patterns. Nickerson (University of Mani-
toba) summarized the recent progress in proteomic profil-
ing using NMR spectroscopy, as well as SELDI-TOF-MS,
showing the presence of b2-microglobulin cleavage prod-
ucts in the urine of patients with tubular dysfunction includ-
ing rejection. Hricik (Case Western Reserve) summarized
the use of the ELISPOT assay to measure IFN-c released
by recipient cells in response to donor cells or donor pep-
tide since the results appear to correlate with subsequent
rejection. Suthanthiran (New York Presbyterian Hospital-
Cornell) summarized results from his laboratory showing a
correlation between the incidence of acute cellular rejec-
tion and CD3, perforin, and Granzyme B levels in urinary
white blood cells measured by PCR. In addition, IP-10 and
CXCR3 levels correlate with renal allograft inflammation
measured by mRNA analysis of urinary white blood cells.
Finally, CD103 or integrin alpha-E correlated with the pres-
ence of acute rejection.
Brennan (Washington University) discussed the concept
of using BK virus infection as a barometer of excessive
immunosuppression. He reported that BK virus infection
typically occurs within months of renal transplantation and
is not dependent on the choice of tacrolimus versus cy-
closporine or the use of MMF versus azathioprine. Since
patients without viruria do not develop viremia, urine PCR
is an excellent screening tool to identify recipients at in-
creased risk. Once viremia is detected, pre-emptive dis-
continuation of either azathioprine or MMF prevents the
progression from viremia to nephropathy. The Cylex im-
munoassay correlated with BK viremia as a marker of over-
immunosuppression.
Conclusion
Approaches for the management of transplant recipients
have evolved substantially over the past decade and ad-
vances in the art and science of immunosuppression are
largely responsible. While the prospect of producing tol-
erance remains elusive, improved understanding of the
biologic consequences of transplantation and administra-
tion of immunosuppression has permitted steady improve-
ments in short-term patient and graft survival through the
implementation of refined immunosuppressive regimens
optimized for reducing adverse side effects and prevent-
ing rejection. It is hoped that the continued application of
this process will result in durable long-term improvements
in quality of life and longevity of transplant recipients in the
years to come.
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